Last updated 12 days ago
A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
1200 patients around the world
Available in Puerto Rico, Brazil, Argentina, Mexico
Eli Lilly and Company
46Research sites
1200Patients around the world
This study is for people with
Alzheimer disease
Requirements for the patient
To 80 Years
All Gender
Medical requirements
- Have a phosphorylated tau (P-tau) result consistent with the presence of amyloid pathology.Have a reliable study partner and backup study partner familiar with overall function and behavior, such as day-to-day activities and cognitive abilities.Have adequate literacy, vision, and hearing for neuropsychological testing at screening.Have a Mini Mental Status Exam (MMSE) score consistent with no to minimal cognitive impairment.Have a Functional Activities Questionnaire (FAQ) score consistent with no to minimal functional impairment.If currently receiving medications as symptomatic treatment for AD, dose has been stable for at least 30 days before screening.
- Have dementia or significant other neurological disease that can affect cognition.Have current serious or unstable illnesses that in the investigator's opinion, could interfere with the analyses of the study.Have a history of cancer that, in the investigator's opinion, has a high risk of recurrence.Have a history of clinically significant multiple or severe drug allergies, or hypersensitivity reactions.Have a clinically important laboratory test result or other abnormality as determined by investigator that could be detrimental to the participant or could compromise the study.Have any contraindications for magnetic resonance imaging (MRI).Have a centrally read MRI demonstrating presence of ARIA-E, >4 cerebral microhemorrhages, any superficial siderosis, any macrohemorrhage, or severe white matter disease at screening.Have had prior treatment with a passive anti-amyloid immunotherapy within <5 half-lives prior to screening.Have received active immunization against Aβ in any other study.
Sites
Instituto Médico de la Fundación Estudios Clínicos - Rosario
STAT Research - CABA
Instituto de Diagnóstico e Investigaciones Metabólicas - IDIM - sede centro - CABA
CIPREC Centro de Investigación y Prevención Cardiovascular - CABA
CEMIC - Hospital Universitario Sede Saavedra - CABA, Buenos Aires
Centro de Investigaciones Metabólicas (CINME) S.A. - CABA, Buenos Aires
Centro de Investigaciones Médicas Tucumán
Consultorios Médicos Dr. Isaac Scherbovsky - Mendoza
Instituto de Neurología Cognitiva (INECO)
Fleni - sede Belgrano
StudyTRAILRUNNER-ALZ 3
SponsorEli Lilly and Company
Study typeInterventional
Conditions
Alzheimer disease
Requirements
To 80 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT06653153
